{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["van Berge Henegouwen JM"],"funding":["Bristol-Myers Squibb","Bayer","Pfizer Pharmaceuticals","Eisai","The Hartwig Medical Foundation","Novartis","Roche","Clovis Oncology","Boehringer Ingelheim","Barcode for Life Foundation","AstraZeneca","Lilly","Amgen Nederland","Janssen Pharmaceuticals","KWF Kankerbestrijding","Merck Sharp and Dohme"],"pagination":["97-104"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9300506"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["90(1)"],"pubmed_abstract":["<h4>Introduction</h4>The combination of vemurafenib, a proto-oncogene B-Raf inhibitor (BRAFi) and cobimetinib, an inhibitor of mitogen-activated protein kinase kinase (MEKi) has shown to improve survival in patients with BRAF V600-mutated melanoma. BRAF mutations are also frequently detected driver mutations in other tumor types, including thyroid carcinoma. Since thyroid carcinoma is not a labeled indication for BRAF/MEKi, a cohort for patients with BRAF V600-mutated thyroid carcinoma was opened within the Drug Rediscovery Protocol (DRUP), a national ongoing pan-cancer multi-drug trial, in which patients receive off-label treatment with approved drugs based on their molecular tumor profile.<h4>Results</h4>Here, we present two patients with BRAF-mutated thyroid carcinoma, who were successf"],"journal":["Cancer chemotherapy and pharmacology"],"pubmed_title":["Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature."],"pmcid":["PMC9300506"],"funding_grant_id":["10014"],"pubmed_authors":["van Berge Henegouwen JM","Meertens M","Zeverijn LJ","Verheul HMW","Gelderblom H","Huitema ADR","Labots M","van der Wijngaart H","Hoes LR","Devriese LA","Voest EE"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.","description":"<h4>Introduction</h4>The combination of vemurafenib, a proto-oncogene B-Raf inhibitor (BRAFi) and cobimetinib, an inhibitor of mitogen-activated protein kinase kinase (MEKi) has shown to improve survival in patients with BRAF V600-mutated melanoma. BRAF mutations are also frequently detected driver mutations in other tumor types, including thyroid carcinoma. Since thyroid carcinoma is not a labeled indication for BRAF/MEKi, a cohort for patients with BRAF V600-mutated thyroid carcinoma was opened within the Drug Rediscovery Protocol (DRUP), a national ongoing pan-cancer multi-drug trial, in which patients receive off-label treatment with approved drugs based on their molecular tumor profile.<h4>Results</h4>Here, we present two patients with BRAF-mutated thyroid carcinoma, who were successf","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-25T18:10:39.324Z","creation":"2024-11-15T12:30:28.778Z"},"accession":"S-EPMC9300506","cross_references":{"pubmed":["35598186"],"doi":["10.1007/s00280-022-04437-z"]}}